In this work, we studied the relative immunogenicity of two recombinant
hepatitis B vaccines (Engerix — B 20 lig and Recombivax HB, 10 ,ug). The
study included 2 groups each 49 medical students immunized with the
vaccination schedule (0,1, and 6 months) Immunogenicity was measured by
determination of anti-HBs, SC, SP and GMT of anti Hns, calculated at
• 1,3,6,8 months afier the initial dose of vaccine. SP rates for subjects
receiving Engerix B, were slightly but not significantly, greater than for the
group at each time point. At 8 months GMT for the group receiving
Engerix — B were significa ntly greater than that for the group receiving
Recombivax HB: 836.6 mIU/m1 versus 340 mllilml (P=0.001). We
concluded that immunization with Engerix — B 20 pg appeared to result in
more and rapid development of sero protective anti — Hits titres in healthy
individuals and in higher titers of anti lib's when compared to the
Recombivax HB, 10 lig dose which suggest that 20 lig dose may result in
long duration of seroprotective anti — Hns titers. |
